Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINO-1713 in healthy Korean female subjects
NCT05677035Phase 1Completed
- Sponsor
- Hyundai Pharmaceutical Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of estetrol and drospirenone in contraception (2 arms), sponsored by Hyundai Pharmaceutical Co., Ltd. Primary endpoints: Maximum Plasma Concentration at 168 hours and Time to Maximum Plasma Concentration at 168 hours. Started Jan 2022; status: completed.
02
Drugs
estetroldrospirenone
03
Conditions
contraception
Beyond the preview
Go deeper on NCT05677035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05677035.